| ■ 영문 제목 : Global Neuromyelitis Optica Spectrum Disorder Market 2023-2027 | |
![]() | ■ 상품코드 : IRTNTR75785-23 ■ 조사/발행회사 : Technavio ■ 발행일 : 2023년 6월 최신판(2025년 또는 2026년)은 문의주세요. ■ 페이지수 : 약120 ■ 작성언어 : 영문 ■ 보고서 형태 : PDF ■ 납품 방식 : E메일 (주문후 24시간내) ■ 조사대상 지역 : 글로벌 ■ 산업 분야 : 의료 |
| Single User (1인 열람용) | USD2,500 ⇒환산₩3,500,000 | 견적의뢰/주문/질문 |
| Enterprise License (기업 열람용) | USD4,000 ⇒환산₩5,600,000 | 견적의뢰/주문/질문 |
|
※가격옵션 설명 - 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다. - 지불방법은 계좌이체/무통장입금 또는 카드결제입니다. |
| 글로벌 시신경 척수염 스펙트럼 장애 (NMOSD) 시장 2023-2027 시신경 척수염 스펙트럼 장애 (NMOSD) 시장은 2022년에서 2027년까지 1억 7,348만 달러 규모로 성장할 것으로 예상되며, 예측 기간 동안 6.16%의 CAGR을 기록할 것으로 예상됩니다. 본 보고서는 시신경 척수염 스펙트럼 장애 (NMOSD) 시장에 대해 시장 규모, 예측, 동향, 성장 촉진요인, 과제 등 전반적인 분석과 함께 약 25개 벤더를 대상으로 한 벤더 분석을 수록하고 있습니다. 현재 시장 시나리오, 최신 동향 및 촉진 요인, 전체 시장 환경에 대한 최신 분석을 제공합니다. 이 시장은 노인 인구의 증가, 새로운 치료제의 승인과 강력한 의약품 파이프라인, 시신경 척수염 스펙트럼 장애 (NMOSD)의 발병률 증가에 의해 주도되고 있습니다. Technavio사의 시신경 척수염 스펙트럼 장애 (NMOSD) 시장은 다음과 같이 분류하고 있습니다. 용도별 - 병원 - 전문 클리닉 - 재택 의료 유형별 - 아쿠아포린-4 항체 있음 - 아쿠아포린-4 항체 없음 지역별 - 북미 - 유럽 - 아시아 - 기타 지역(ROW) 이 연구는 향후 몇 년 동안 시신경 척수염 스펙트럼 장애 (NMOSD) 시장의 성장을 촉진하는 주요 이유 중 하나로 NMOSD 치료의 발전을 꼽고 있습니다. 또한, 의료 비용의 증가와 전략적 제휴의 증가는 시장의 큰 수요로 이어질 것으로 예상되고 있습니다. 시신경 척수염 스펙트럼 장애 (NMOSD) 시장에 대한 연구 보고서는 다음과 같은 분야를 다루고 있습니다. - 시신경 척수염 스펙트럼 장애 (NMOSD) 시장 규모 - 시신경 척수염 스펙트럼 장애 (NMOSD) 시장 예측 - 시신경 척수염 스펙트럼 장애 (NMOSD)시장 산업 분석 강력한 벤더 분석은 고객이 시장 지위를 향상시킬 수 있도록 설계되었으며, 이에 따라 이 보고서에서는 AstraZeneca, Biogen Inc., Chugai Pharmaceutical Co. Ltd., F. Hoffmann La Roche Ltd., HBM Holdings Ltd., Horizon Therapeutics Plc, TG Therapeutics Inc., Mitsubishi Chemical Group Corp., 및 Opexa Therapeutics Inc. 등의 기업 정보를 수록하고 있습니다. 또한, 시신경 척수염 스펙트럼 장애 (NMOSD) 시장 분석 보고서에는 시장 성장에 영향을 미치는 향후 동향과 과제에 대한 정보도 포함되어 있습니다. 이는 기업이 전략을 수립하고 다가오는 모든 성장 기회를 활용하는 데 도움이 될 것으로 예상되고 있습니다. 이 연구는 업계 주요 참여자들의 의견을 포함하여 1차 및 2차 정보를 객관적으로 결합하여 수행되었습니다. 이 보고서는 주요 벤더에 대한 분석과 함께 포괄적인 시장 및 벤더 현황을 제공합니다. 이 보고서는 이익, 가격, 경쟁, 프로모션 등 주요 매개변수를 분석하여 여러 출처의 데이터를 조사, 통합, 요약하는 방식으로 시장의 상세한 모습을 제시합니다. 또한, 주요 산업 영향력자를 식별하여 시장의 다양한 측면을 제시합니다. 제시된 데이터는 포괄적이고 신뢰할 수 있는 1차 및 2차에 걸친 광범위한 조사 결과입니다. 시장 조사 보고서는 정확한 시장 성장을 예측하기 위해 완전한 경쟁 환경과 정성적 및 정량적 조사를 통한 면밀한 공급업체 선정 방법 및 분석을 제공합니다. |
1. 개요
2. 세계의 시신경 척수염 스펙트럼 장애 (NMOSD) 시장 현황
3. 세계의 시신경 척수염 스펙트럼 장애 (NMOSD) 시장 규모
4. 과거 시장 규모
5. 파이브 포스 분석
6. 용도별 시장 분석
7. 유형별 시장 분석
8. 고객 현황
9. 지역별 분석
10. 추진 요인/과제/동향
11. 기업 현황
12. 기업 분석
13. 부록
1 요약 3 시장 규모 o 표 23: 5가지 경쟁요인 분석 – 2022년과 2027년 비교 o 표 38: 전문 클리닉 차트 – 2022-2027년 시장 규모 및 전망 (백만 달러) 7 유형별 시장 세분화 8 고객 현황 o 표 67: 북미 시장 규모 및 전망 2022-2027년 차트(백만 달러) o 표 79: 기타 지역 (ROW) – 시장 규모 및 전망 2022-2027 (백만 달러) o 표 82: 기타 지역 (ROW) – 전년 대비 성장률 2022-2027 (%) 12. 벤더 분석 o 표 119: 주가이 제약 주식회사 – 제품/서비스 o 표 126: HBM 홀딩스 주식회사 – 개요 첨부 자료: 표 1: 요약 – 시장 개요 차트 첨부자료 101: 인도 시장 차트 – 2022-2027년 전년 대비 성장률(%) 첨부자료 137: 미쓰비시 화학 그룹(Mitsubishi Chemical Group Corp.) – 사업 부문 집중 분석 o 1.1 Market overview o Exhibit 01: Executive Summary - Chart on Market Overview o Exhibit 02: Executive Summary - Data Table on Market Overview o Exhibit 03: Executive Summary - Chart on Global Market Characteristics o Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape o Exhibit 05: Executive Summary - Chart on Market Segmentation by Application o Exhibit 06: Executive Summary - Chart on Market Segmentation by Type o Exhibit 07: Executive Summary - Chart on Incremental Growth o Exhibit 08: Executive Summary - Data Table on Incremental Growth o Exhibit 09: Executive Summary - Chart on Vendor Market Positioning 2 Market Landscape o 2.1 Market ecosystem o Exhibit 10: Parent market o Exhibit 11: Market Characteristics 3 Market Sizing o 3.1 Market definition o Exhibit 12: Offerings of vendors included in the market definition o 3.2 Market segment analysis o Exhibit 13: Market segments o 3.3 Market size 2022 o 3.4 Market outlook: Forecast for 2022-2027 o Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million) o Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million) o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%) o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%) 4 Historic Market Size o 4.1 Global neuromyelitis optica spectrum disorder market 2017 - 2021 o Exhibit 18: Historic Market Size - Data Table on global neuromyelitis optica spectrum disorder market 2017 - 2021 ($ million) o 4.2 Application Segment Analysis 2017 - 2021 o Exhibit 19: Historic Market Size - Application Segment 2017 - 2021 ($ million) o 4.3 Type Segment Analysis 2017 - 2021 o Exhibit 20: Historic Market Size - Type Segment 2017 - 2021 ($ million) o 4.4 Geography Segment Analysis 2017 - 2021 o Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million) o 4.5 Country Segment Analysis 2017 - 2021 o Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million) 5 Five Forces Analysis o 5.1 Five forces summary o Exhibit 23: Five forces analysis - Comparison between 2022 and 2027 o 5.2 Bargaining power of buyers o Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027 o 5.3 Bargaining power of suppliers o Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027 o 5.4 Threat of new entrants o Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027 o 5.5 Threat of substitutes o Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027 o 5.6 Threat of rivalry o Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027 o 5.7 Market condition o Exhibit 29: Chart on Market condition - Five forces 2022 and 2027 6 Market Segmentation by Application o 6.1 Market segments o Exhibit 30: Chart on Application - Market share 2022-2027 (%) o Exhibit 31: Data Table on Application - Market share 2022-2027 (%) o 6.2 Comparison by Application o Exhibit 32: Chart on Comparison by Application o Exhibit 33: Data Table on Comparison by Application o 6.3 Hospitals - Market size and forecast 2022-2027 o Exhibit 34: Chart on Hospitals - Market size and forecast 2022-2027 ($ million) o Exhibit 35: Data Table on Hospitals - Market size and forecast 2022-2027 ($ million) o Exhibit 36: Chart on Hospitals - Year-over-year growth 2022-2027 (%) o Exhibit 37: Data Table on Hospitals - Year-over-year growth 2022-2027 (%) o 6.4 Speciality clinics - Market size and forecast 2022-2027 o Exhibit 38: Chart on Speciality clinics - Market size and forecast 2022-2027 ($ million) o Exhibit 39: Data Table on Speciality clinics - Market size and forecast 2022-2027 ($ million) o Exhibit 40: Chart on Speciality clinics - Year-over-year growth 2022-2027 (%) o Exhibit 41: Data Table on Speciality clinics - Year-over-year growth 2022-2027 (%) o 6.5 Homecare - Market size and forecast 2022-2027 o Exhibit 42: Chart on Homecare - Market size and forecast 2022-2027 ($ million) o Exhibit 43: Data Table on Homecare - Market size and forecast 2022-2027 ($ million) o Exhibit 44: Chart on Homecare - Year-over-year growth 2022-2027 (%) o Exhibit 45: Data Table on Homecare - Year-over-year growth 2022-2027 (%) o 6.6 Market opportunity by Application o Exhibit 46: Market opportunity by Application ($ million) o Exhibit 47: Data Table on Market opportunity by Application ($ million) 7 Market Segmentation by Type o 7.1 Market segments o Exhibit 48: Chart on Type - Market share 2022-2027 (%) o Exhibit 49: Data Table on Type - Market share 2022-2027 (%) o 7.2 Comparison by Type o Exhibit 50: Chart on Comparison by Type o Exhibit 51: Data Table on Comparison by Type o 7.3 With aquaporin-4 antibodies - Market size and forecast 2022-2027 o Exhibit 52: Chart on With aquaporin-4 antibodies - Market size and forecast 2022-2027 ($ million) o Exhibit 53: Data Table on With aquaporin-4 antibodies - Market size and forecast 2022-2027 ($ million) o Exhibit 54: Chart on With aquaporin-4 antibodies - Year-over-year growth 2022-2027 (%) o Exhibit 55: Data Table on With aquaporin-4 antibodies - Year-over-year growth 2022-2027 (%) o 7.4 Without aquaporin-4 antibodies - Market size and forecast 2022-2027 o Exhibit 56: Chart on Without aquaporin-4 antibodies - Market size and forecast 2022-2027 ($ million) o Exhibit 57: Data Table on Without aquaporin-4 antibodies - Market size and forecast 2022-2027 ($ million) o Exhibit 58: Chart on Without aquaporin-4 antibodies - Year-over-year growth 2022-2027 (%) o Exhibit 59: Data Table on Without aquaporin-4 antibodies - Year-over-year growth 2022-2027 (%) o 7.5 Market opportunity by Type o Exhibit 60: Market opportunity by Type ($ million) o Exhibit 61: Data Table on Market opportunity by Type ($ million) 8 Customer Landscape o 8.1 Customer landscape overview o Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 9 Geographic Landscape o 9.1 Geographic segmentation o Exhibit 63: Chart on Market share By Geographical Landscape 2022-2027 (%) o Exhibit 64: Data Table on Market share By Geographical Landscape 2022-2027 (%) o 9.2 Geographic comparison o Exhibit 65: Chart on Geographic comparison o Exhibit 66: Data Table on Geographic comparison o 9.3 North America - Market size and forecast 2022-2027 o Exhibit 67: Chart on North America - Market size and forecast 2022-2027 ($ million) o Exhibit 68: Data Table on North America - Market size and forecast 2022-2027 ($ million) o Exhibit 69: Chart on North America - Year-over-year growth 2022-2027 (%) o Exhibit 70: Data Table on North America - Year-over-year growth 2022-2027 (%) o 9.4 Europe - Market size and forecast 2022-2027 o Exhibit 71: Chart on Europe - Market size and forecast 2022-2027 ($ million) o Exhibit 72: Data Table on Europe - Market size and forecast 2022-2027 ($ million) o Exhibit 73: Chart on Europe - Year-over-year growth 2022-2027 (%) o Exhibit 74: Data Table on Europe - Year-over-year growth 2022-2027 (%) o 9.5 Asia - Market size and forecast 2022-2027 o Exhibit 75: Chart on Asia - Market size and forecast 2022-2027 ($ million) o Exhibit 76: Data Table on Asia - Market size and forecast 2022-2027 ($ million) o Exhibit 77: Chart on Asia - Year-over-year growth 2022-2027 (%) o Exhibit 78: Data Table on Asia - Year-over-year growth 2022-2027 (%) o 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 o Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) o Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) o Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) o Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) o 9.7 US - Market size and forecast 2022-2027 o Exhibit 83: Chart on US - Market size and forecast 2022-2027 ($ million) o Exhibit 84: Data Table on US - Market size and forecast 2022-2027 ($ million) o Exhibit 85: Chart on US - Year-over-year growth 2022-2027 (%) o Exhibit 86: Data Table on US - Year-over-year growth 2022-2027 (%) o 9.8 UK - Market size and forecast 2022-2027 o Exhibit 87: Chart on UK - Market size and forecast 2022-2027 ($ million) o Exhibit 88: Data Table on UK - Market size and forecast 2022-2027 ($ million) o Exhibit 89: Chart on UK - Year-over-year growth 2022-2027 (%) o Exhibit 90: Data Table on UK - Year-over-year growth 2022-2027 (%) o 9.9 China - Market size and forecast 2022-2027 o Exhibit 91: Chart on China - Market size and forecast 2022-2027 ($ million) o Exhibit 92: Data Table on China - Market size and forecast 2022-2027 ($ million) o Exhibit 93: Chart on China - Year-over-year growth 2022-2027 (%) o Exhibit 94: Data Table on China - Year-over-year growth 2022-2027 (%) o 9.10 Canada - Market size and forecast 2022-2027 o Exhibit 95: Chart on Canada - Market size and forecast 2022-2027 ($ million) o Exhibit 96: Data Table on Canada - Market size and forecast 2022-2027 ($ million) o Exhibit 97: Chart on Canada - Year-over-year growth 2022-2027 (%) o Exhibit 98: Data Table on Canada - Year-over-year growth 2022-2027 (%) o 9.11 India - Market size and forecast 2022-2027 o Exhibit 99: Chart on India - Market size and forecast 2022-2027 ($ million) o Exhibit 100: Data Table on India - Market size and forecast 2022-2027 ($ million) o Exhibit 101: Chart on India - Year-over-year growth 2022-2027 (%) o Exhibit 102: Data Table on India - Year-over-year growth 2022-2027 (%) o 9.12 Market opportunity By Geographical Landscape o Exhibit 103: Market opportunity By Geographical Landscape ($ million) o Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ million) 10 Drivers, Challenges, and Trends o 10.1 Market drivers o 10.2 Market challenges o 10.3 Impact of drivers and challenges o Exhibit 105: Impact of drivers and challenges in 2022 and 2027 o 10.4 Market trends 11 Vendor Landscape o 11.1 Overview o 11.2 Vendor landscape o Exhibit 106: Overview on Criticality of inputs and Factors of differentiation o 11.3 Landscape disruption o Exhibit 107: Overview on factors of disruption o 11.4 Industry risks o Exhibit 108: Impact of key risks on business 12 Vendor Analysis o 12.1 Vendors covered o Exhibit 109: Vendors covered o 12.2 Market positioning of vendors o Exhibit 110: Matrix on vendor position and classification o 12.3 AstraZeneca o Exhibit 111: AstraZeneca - Overview o Exhibit 112: AstraZeneca - Product / Service o Exhibit 113: AstraZeneca - Key news o Exhibit 114: AstraZeneca - Key offerings o 12.4 Biogen Inc. o Exhibit 115: Biogen Inc. - Overview o Exhibit 116: Biogen Inc. - Product / Service o Exhibit 117: Biogen Inc. - Key offerings o 12.5 Chugai Pharmaceutical Co. Ltd. o Exhibit 118: Chugai Pharmaceutical Co. Ltd. - Overview o Exhibit 119: Chugai Pharmaceutical Co. Ltd. - Product / Service o Exhibit 120: Chugai Pharmaceutical Co. Ltd. - Key offerings o 12.6 F. Hoffmann La Roche Ltd. o Exhibit 121: F. Hoffmann La Roche Ltd. - Overview o Exhibit 122: F. Hoffmann La Roche Ltd. - Business segments o Exhibit 123: F. Hoffmann La Roche Ltd. - Key news o Exhibit 124: F. Hoffmann La Roche Ltd. - Key offerings o Exhibit 125: F. Hoffmann La Roche Ltd. - Segment focus o 12.7 HBM Holdings Ltd. o Exhibit 126: HBM Holdings Ltd. - Overview o Exhibit 127: HBM Holdings Ltd. - Product / Service o Exhibit 128: HBM Holdings Ltd. - Key offerings o 12.8 Horizon Therapeutics Plc o Exhibit 129: Horizon Therapeutics Plc - Overview o Exhibit 130: Horizon Therapeutics Plc - Business segments o Exhibit 131: Horizon Therapeutics Plc - Key news o Exhibit 132: Horizon Therapeutics Plc - Key offerings o Exhibit 133: Horizon Therapeutics Plc - Segment focus o 12.9 Mitsubishi Chemical Group Corp. o Exhibit 134: Mitsubishi Chemical Group Corp. - Overview o Exhibit 135: Mitsubishi Chemical Group Corp. - Business segments o Exhibit 136: Mitsubishi Chemical Group Corp. - Key offerings o Exhibit 137: Mitsubishi Chemical Group Corp. - Segment focus o 12.10 Opexa Therapeutics Inc. o Exhibit 138: Opexa Therapeutics Inc. - Overview o Exhibit 139: Opexa Therapeutics Inc. - Product / Service o Exhibit 140: Opexa Therapeutics Inc. - Key offerings o 12.11 TG Therapeutics Inc. o Exhibit 141: TG Therapeutics Inc. - Overview o Exhibit 142: TG Therapeutics Inc. - Product / Service o Exhibit 143: TG Therapeutics Inc. - Key offerings 13 Appendix o 13.1 Scope of the report o 13.2 Inclusions and exclusions checklist o Exhibit 144: Inclusions checklist o Exhibit 145: Exclusions checklist o 13.3 Currency conversion rates for US$ o Exhibit 146: Currency conversion rates for US$ o 13.4 Research methodology o Exhibit 147: Research methodology o Exhibit 148: Validation techniques employed for market sizing o Exhibit 149: Information sources o 13.5 List of abbreviations o Exhibit 150: List of abbreviations Exhibits: Exhibits1: Executive Summary - Chart on Market Overview Exhibits2: Executive Summary - Data Table on Market Overview Exhibits3: Executive Summary - Chart on Global Market Characteristics Exhibits4: Executive Summary - Chart on Market By Geographical Landscape Exhibits5: Executive Summary - Chart on Market Segmentation by Application Exhibits6: Executive Summary - Chart on Market Segmentation by Type Exhibits7: Executive Summary - Chart on Incremental Growth Exhibits8: Executive Summary - Data Table on Incremental Growth Exhibits9: Executive Summary - Chart on Vendor Market Positioning Exhibits10: Parent market Exhibits11: Market Characteristics Exhibits12: Offerings of vendors included in the market definition Exhibits13: Market segments Exhibits14: Chart on Global - Market size and forecast 2022-2027 ($ million) Exhibits15: Data Table on Global - Market size and forecast 2022-2027 ($ million) Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%) Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%) Exhibits18: Historic Market Size - Data Table on global neuromyelitis optica spectrum disorder market 2017 - 2021 ($ million) Exhibits19: Historic Market Size - Application Segment 2017 - 2021 ($ million) Exhibits20: Historic Market Size - Type Segment 2017 - 2021 ($ million) Exhibits21: Historic Market Size - Geography Segment 2017 - 2021 ($ million) Exhibits22: Historic Market Size - Country Segment 2017 - 2021 ($ million) Exhibits23: Five forces analysis - Comparison between 2022 and 2027 Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027 Exhibits25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027 Exhibits26: Threat of new entrants - Impact of key factors in 2022 and 2027 Exhibits27: Threat of substitutes - Impact of key factors in 2022 and 2027 Exhibits28: Threat of rivalry - Impact of key factors in 2022 and 2027 Exhibits29: Chart on Market condition - Five forces 2022 and 2027 Exhibits30: Chart on Application - Market share 2022-2027 (%) Exhibits31: Data Table on Application - Market share 2022-2027 (%) Exhibits32: Chart on Comparison by Application Exhibits33: Data Table on Comparison by Application Exhibits34: Chart on Hospitals - Market size and forecast 2022-2027 ($ million) Exhibits35: Data Table on Hospitals - Market size and forecast 2022-2027 ($ million) Exhibits36: Chart on Hospitals - Year-over-year growth 2022-2027 (%) Exhibits37: Data Table on Hospitals - Year-over-year growth 2022-2027 (%) Exhibits38: Chart on Speciality clinics - Market size and forecast 2022-2027 ($ million) Exhibits39: Data Table on Speciality clinics - Market size and forecast 2022-2027 ($ million) Exhibits40: Chart on Speciality clinics - Year-over-year growth 2022-2027 (%) Exhibits41: Data Table on Speciality clinics - Year-over-year growth 2022-2027 (%) Exhibits42: Chart on Homecare - Market size and forecast 2022-2027 ($ million) Exhibits43: Data Table on Homecare - Market size and forecast 2022-2027 ($ million) Exhibits44: Chart on Homecare - Year-over-year growth 2022-2027 (%) Exhibits45: Data Table on Homecare - Year-over-year growth 2022-2027 (%) Exhibits46: Market opportunity by Application ($ million) Exhibits47: Data Table on Market opportunity by Application ($ million) Exhibits48: Chart on Type - Market share 2022-2027 (%) Exhibits49: Data Table on Type - Market share 2022-2027 (%) Exhibits50: Chart on Comparison by Type Exhibits51: Data Table on Comparison by Type Exhibits52: Chart on With aquaporin-4 antibodies - Market size and forecast 2022-2027 ($ million) Exhibits53: Data Table on With aquaporin-4 antibodies - Market size and forecast 2022-2027 ($ million) Exhibits54: Chart on With aquaporin-4 antibodies - Year-over-year growth 2022-2027 (%) Exhibits55: Data Table on With aquaporin-4 antibodies - Year-over-year growth 2022-2027 (%) Exhibits56: Chart on Without aquaporin-4 antibodies - Market size and forecast 2022-2027 ($ million) Exhibits57: Data Table on Without aquaporin-4 antibodies - Market size and forecast 2022-2027 ($ million) Exhibits58: Chart on Without aquaporin-4 antibodies - Year-over-year growth 2022-2027 (%) Exhibits59: Data Table on Without aquaporin-4 antibodies - Year-over-year growth 2022-2027 (%) Exhibits60: Market opportunity by Type ($ million) Exhibits61: Data Table on Market opportunity by Type ($ million) Exhibits62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria Exhibits63: Chart on Market share By Geographical Landscape 2022-2027 (%) Exhibits64: Data Table on Market share By Geographical Landscape 2022-2027 (%) Exhibits65: Chart on Geographic comparison Exhibits66: Data Table on Geographic comparison Exhibits67: Chart on North America - Market size and forecast 2022-2027 ($ million) Exhibits68: Data Table on North America - Market size and forecast 2022-2027 ($ million) Exhibits69: Chart on North America - Year-over-year growth 2022-2027 (%) Exhibits70: Data Table on North America - Year-over-year growth 2022-2027 (%) Exhibits71: Chart on Europe - Market size and forecast 2022-2027 ($ million) Exhibits72: Data Table on Europe - Market size and forecast 2022-2027 ($ million) Exhibits73: Chart on Europe - Year-over-year growth 2022-2027 (%) Exhibits74: Data Table on Europe - Year-over-year growth 2022-2027 (%) Exhibits75: Chart on Asia - Market size and forecast 2022-2027 ($ million) Exhibits76: Data Table on Asia - Market size and forecast 2022-2027 ($ million) Exhibits77: Chart on Asia - Year-over-year growth 2022-2027 (%) Exhibits78: Data Table on Asia - Year-over-year growth 2022-2027 (%) Exhibits79: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibits80: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibits81: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) Exhibits82: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) Exhibits83: Chart on US - Market size and forecast 2022-2027 ($ million) Exhibits84: Data Table on US - Market size and forecast 2022-2027 ($ million) Exhibits85: Chart on US - Year-over-year growth 2022-2027 (%) Exhibits86: Data Table on US - Year-over-year growth 2022-2027 (%) Exhibits87: Chart on UK - Market size and forecast 2022-2027 ($ million) Exhibits88: Data Table on UK - Market size and forecast 2022-2027 ($ million) Exhibits89: Chart on UK - Year-over-year growth 2022-2027 (%) Exhibits90: Data Table on UK - Year-over-year growth 2022-2027 (%) Exhibits91: Chart on China - Market size and forecast 2022-2027 ($ million) Exhibits92: Data Table on China - Market size and forecast 2022-2027 ($ million) Exhibits93: Chart on China - Year-over-year growth 2022-2027 (%) Exhibits94: Data Table on China - Year-over-year growth 2022-2027 (%) Exhibits95: Chart on Canada - Market size and forecast 2022-2027 ($ million) Exhibits96: Data Table on Canada - Market size and forecast 2022-2027 ($ million) Exhibits97: Chart on Canada - Year-over-year growth 2022-2027 (%) Exhibits98: Data Table on Canada - Year-over-year growth 2022-2027 (%) Exhibits99: Chart on India - Market size and forecast 2022-2027 ($ million) Exhibits100: Data Table on India - Market size and forecast 2022-2027 ($ million) Exhibits101: Chart on India - Year-over-year growth 2022-2027 (%) Exhibits102: Data Table on India - Year-over-year growth 2022-2027 (%) Exhibits103: Market opportunity By Geographical Landscape ($ million) Exhibits104: Data Tables on Market opportunity By Geographical Landscape ($ million) Exhibits105: Impact of drivers and challenges in 2022 and 2027 Exhibits106: Overview on Criticality of inputs and Factors of differentiation Exhibits107: Overview on factors of disruption Exhibits108: Impact of key risks on business Exhibits109: Vendors covered Exhibits110: Matrix on vendor position and classification Exhibits111: AstraZeneca - Overview Exhibits112: AstraZeneca - Product / Service Exhibits113: AstraZeneca - Key news Exhibits114: AstraZeneca - Key offerings Exhibits115: Biogen Inc. - Overview Exhibits116: Biogen Inc. - Product / Service Exhibits117: Biogen Inc. - Key offerings Exhibits118: Chugai Pharmaceutical Co. Ltd. - Overview Exhibits119: Chugai Pharmaceutical Co. Ltd. - Product / Service Exhibits120: Chugai Pharmaceutical Co. Ltd. - Key offerings Exhibits121: F. Hoffmann La Roche Ltd. - Overview Exhibits122: F. Hoffmann La Roche Ltd. - Business segments Exhibits123: F. Hoffmann La Roche Ltd. - Key news Exhibits124: F. Hoffmann La Roche Ltd. - Key offerings Exhibits125: F. Hoffmann La Roche Ltd. - Segment focus Exhibits126: HBM Holdings Ltd. - Overview Exhibits127: HBM Holdings Ltd. - Product / Service Exhibits128: HBM Holdings Ltd. - Key offerings Exhibits129: Horizon Therapeutics Plc - Overview Exhibits130: Horizon Therapeutics Plc - Business segments Exhibits131: Horizon Therapeutics Plc - Key news Exhibits132: Horizon Therapeutics Plc - Key offerings Exhibits133: Horizon Therapeutics Plc - Segment focus Exhibits134: Mitsubishi Chemical Group Corp. - Overview Exhibits135: Mitsubishi Chemical Group Corp. - Business segments Exhibits136: Mitsubishi Chemical Group Corp. - Key offerings Exhibits137: Mitsubishi Chemical Group Corp. - Segment focus Exhibits138: Opexa Therapeutics Inc. - Overview Exhibits139: Opexa Therapeutics Inc. - Product / Service Exhibits140: Opexa Therapeutics Inc. - Key offerings Exhibits141: TG Therapeutics Inc. - Overview Exhibits142: TG Therapeutics Inc. - Product / Service Exhibits143: TG Therapeutics Inc. - Key offerings Exhibits144: Inclusions checklist Exhibits145: Exclusions checklist Exhibits146: Currency conversion rates for US$ Exhibits147: Research methodology Exhibits148: Validation techniques employed for market sizing Exhibits149: Information sources Exhibits150: List of abbreviations |
| ※참고 정보 시신경 척수염 스펙트럼 장애(Neuromyelitis Optica Spectrum Disorder, NMOSD)는 주로 시신경과 척수에 영향을 미치는 자가면역 질환으로, 주로 면역 체계가 신경 조직을 공격하여 염증을 일으키는 것이 특징입니다. 이 질환은 일반적으로 소모성 염증 반응이 발생하여 시각 상실이나 운동 장애와 같은 심각한 신경학적 증상을 초래할 수 있습니다. NMOSD는 19세기 후반에 처음으로 기술되었으며, 주로 이 질환을 앓는 환자들은 자주 재발하는 증상을 보입니다. NMOSD의 핵심 특징 중 하나는 'AQP4 항체'의 존재입니다. AQP4는 신경 세포의 아스트로글리아 세포에서 발현되는 수용체로, 이 항체가 생성되면 신경계에서 염증을 유발합니다. 이러한 AQP4 항체는 NMOSD의 진단 마커로 활용되며, 약 60%에서 80%의 환자에서 확인됩니다. 그러나 AQP4 항체가 없는 경우도 있으며, 이는 'AQP4 음성 NMOSD'로 분류됩니다. NMOSD는 이외에도 다양한 분류로 나뉘는데, 가장 일반적인 형태는 두 가지로 나뉘어져 있습니다. 첫째는 발작성 경과를 보이는 환자들로, 급성이자 재발하는 증상을 겪습니다. 둘째는 단발적인 증상으로 끝나는 환자들로, 재발 없이 증상이 제한적입니다. 이외에도 NMOSD는 다른 질환과 동반될 수 있으며, 여러 신경 증상이 동반되는 경우도 있습니다. 이는 질병의 임상적 특성을 복잡하게 만들어 진단 및 치료를 더욱 어렵게 합니다. NMOSD의 주요 증상으로는 시각 장애(예: 시신경염), 운동 기능 저하(예: 척수염으로 인한 마비), 및 감각 이상 등이 있습니다. 이러한 증상들은 종종 급성으로 나타나며, 환자의 생활에 상당한 영향을 미치게 됩니다. 특히, 시각 장애는 환자에게 큰 심리적 충격을 줄 수 있으며, 상태에 따라 완전한 시각 손실로 이어질 수 있습니다. NMOSD의 진단은 임상 증상, MRI 검사, 혈액 검사(특히 AQP4 항체 검사를 포함) 등을 종합적으로 통해 이루어집니다. 이러한 진단 과정은 반드시 전문적인 신경과 의사의 검토가 필요하며, 정확한 진단이 치료 계획의 결정에 있어 매우 중요합니다. 치료 방법은 주로 급성 증상을 완화하기 위한 스타로이드 치료와 면역 억제제 사용으로 구분됩니다. 환자의 상태에 따라 항체의 존재 여부에 따라 약물이 다르게 적용될 수 있으며, 초기 치료가 성공적으로 이루어질 경우 합병증 예방과 장기적인 기능 유지에 긍정적인 영향을 미칠 수 있습니다. 최근에는 NMOSD의 표적 치료제들이 개발되고 있으며, 이러한 약물들은 더 나은 치료 결과를 가져오는 데 기여하고 있습니다. NMOSD와 관련된 연구는 현재도 활발히 이루어지고 있으며, 향후 더욱 효과적인 치료법과 조기 진단 방법이 개발되기를 기대하고 있습니다. 이 질환은 질병의 이해와 진단, 치료법 개선이 필요한 복잡한 영역으로, 환자와 가족들에게 큰 부담을 주는 만큼, 사회적인 인식 제고와 지원 시스템 강화가 필수적입니다. |
| ※본 조사보고서 [글로벌 시신경 척수염 스펙트럼 장애 (NMOSD) 시장 2023-2027 : 병원, 전문 클리닉, 재택 의료] (코드 : IRTNTR75785-23) 판매에 관한 면책사항을 반드시 확인하세요. |
| ※본 조사보고서 [글로벌 시신경 척수염 스펙트럼 장애 (NMOSD) 시장 2023-2027 : 병원, 전문 클리닉, 재택 의료] 에 대해서 E메일 문의는 여기를 클릭하세요. |

